The MOSAIC and NSABP C-07 Trials
The MOSAIC trial (Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) and the NSABP C-07 trial were the two pivotal randomized controlled trials that established oxaliplatin-based chemotherapy as the standard of care for stage III colon cancer in the adjuvant setting. 1
MOSAIC Trial Design and Key Findings
The MOSAIC trial was an international, multicenter, randomized (1:1) trial that enrolled 2,246 patients with completely resected stage II (Dukes' B2) or stage III (Dukes' C) colon cancer 1. Patients were randomized to receive either:
- FOLFOX4 arm (N=1,123): Oxaliplatin 85 mg/m² on day 1 + infusional 5-FU/leucovorin (LV 200 mg/m² followed by FU 400 mg/m² bolus and 600 mg/m² 22-hour infusion on days 1 and 2), every 2 weeks for 12 cycles (6 months total)
- Control arm (N=1,123): Infusional 5-FU/leucovorin alone on the same schedule
Primary outcome was 3-year disease-free survival (DFS). At 10-year follow-up, the trial demonstrated significant overall survival benefit: 10-year OS rates were 71.7% with FOLFOX4 versus 67.1% with 5-FU/LV alone (HR 0.85, P=0.043) 2. The benefit was most pronounced in stage III disease (67.1% vs 59.0%, HR 0.80, P=0.016), while stage II patients showed no OS benefit (78.4% vs 79.5%, HR 1.00, P=0.980) 2.
NSABP C-07 Trial Design and Key Findings
The NSABP C-07 trial enrolled 2,407 eligible patients with stage II or III colon cancer who underwent potentially curative resection 3, 4. This trial used a bolus 5-FU regimen rather than infusional, randomizing patients to:
- FLOX arm: Bolus 5-FU 500 mg/m² IV weekly for 6 weeks + leucovorin 500 mg/m² IV weekly for 6 weeks + oxaliplatin 85 mg/m² IV on weeks 1,3, and 5 of each 8-week cycle for 3 cycles
- FULV arm: Bolus 5-FU/leucovorin alone on the same schedule
The trial demonstrated a 20% reduction in disease recurrence risk (HR 0.80,95% CI 0.69-0.93, P<0.004) with the addition of oxaliplatin 4. The 4-year DFS rates were 73.2% for FLOX versus 67.0% for FULV 4. However, at 8-year median follow-up, overall survival did not reach statistical significance (HR 0.88,95% CI 0.75-1.02, P=0.08) 3.
Critical Differences Between the Trials
The key distinction is the fluoropyrimidine backbone: MOSAIC used infusional 5-FU (FOLFOX), while NSABP C-07 used bolus 5-FU (FLOX) 1, 4. This difference has important clinical implications, as the FLOX regimen was associated with higher rates of severe diarrhea and bowel wall thickening (5.5% hospitalization rate for diarrhea with FLOX vs 3.0% with FULV alone) 4.
Toxicity Profiles
Both trials demonstrated that oxaliplatin addition significantly increased peripheral sensory neuropathy:
- MOSAIC: Grade 3-4 peripheral sensory neuropathy occurred during treatment, with the majority of cases being reversible 5
- NSABP C-07: Grade 3 neurosensory toxicity occurred in 8.2% of FLOX patients versus 0.7% of FULV patients (P<0.001) 4
Treatment-related mortality was low and similar between arms in both trials (0.5% in MOSAIC, 1.2% within 60 days in C-07) 1, 4.
Current Clinical Application
Based on these landmark trials, FOLFOX (infusional regimen) became the preferred oxaliplatin-containing adjuvant regimen for stage III colon cancer rather than FLOX, due to better tolerability and demonstrated OS benefit 6, 7. The MOSAIC trial's use of infusional 5-FU provided the foundation for current practice guidelines recommending oxaliplatin-based adjuvant therapy specifically for stage III disease 6, 7.
Important caveat: Subsequent analyses revealed that patients ≥70 years in NSABP C-07 did not demonstrate OS benefit from oxaliplatin (interaction P=0.039), though DFS benefit was maintained 3. This age-related finding has influenced contemporary treatment discussions, though more recent pooled analyses suggest that fit older patients enrolled in clinical trials may still benefit when time to recurrence is used as the endpoint 8.